Free tool
FAERS Monitor: Ziana
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050802 or its brand name (Ziana, Clindamycin Phosphate, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
154
Serious
59
38% of reports
Hospitalization
25
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective17
- acne11
- headache8
- nausea8
- pain7
- diarrhoea6
- dizziness6
- dry skin6
- erythema6
- application site erythema5
- application site pain5
- flushing5
- injury5
- product use issue5
- accidental exposure to product4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 7 |
| 2014 | 23 |
| 2015 | 20 |
| 2016 | 40 |
| 2017 | 6 |
| 2018 | 9 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,005 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site painSignal | 5 | 31.0 | 13.1 | 117 |
| application site erythemaSignal | 5 | 26.1 | 11.0 | 97 |
| acneSignal | 11 | 19.8 | 11.2 | 179 |
| injurySignal | 5 | 9.7 | 4.1 | 31 |
| flushingSignal | 5 | 6.7 | 2.8 | 19 |
| dry skinSignal | 6 | 6.1 | 2.8 | 21 |
| accidental exposure to productSignal | 4 | 5.3 | 2.0 | 10 |
| erythemaSignal | 6 | 4.0 | 1.8 | 11 |
| product use issueSignal | 5 | 3.6 | 1.5 | 7 |
| drug ineffective | 17 | 1.8 | 1.1 | 5 |
| headache | 8 | 1.7 | 0.9 | 2 |
| dizziness | 6 | 1.6 | 0.7 | 1 |
| pain | 7 | 1.6 | 0.8 | 1 |
| nausea | 8 | 1.4 | 0.7 | 1 |
| diarrhoea | 6 | 1.3 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.